Fluoroquinolone antibacterial eye drops: effects on normal human corneal epithelium, stroma, and endothelium

Ryou Watanabe, Toru Nakazawa, Shunji Yokokura, Akira Kubota, Hisayo Kubota, Kohji Nishida, Ryou Watanabe, Toru Nakazawa, Shunji Yokokura, Akira Kubota, Hisayo Kubota, Kohji Nishida

Abstract

Background: In vitro studies have suggested the corneal cytotoxicity of third-generation fluoroquinolone levofloxacin (LVFX) and fourth-generation fluoroquinolone moxifloxacin hydrochloride (MFLX) among fluoroquinolone antibacterial eye drops. This study investigated the effects of these two eye drops on the human cornea in vivo.

Methods: We evaluated 30 healthy adults (19 men and 11 women, 38.3 ± 6.3 years old). Each subject received an LVFX ophthalmic solution 0.5% in one eye and an MFLX ophthalmic solution 0.5% in the other eye three times daily for 7 days. Functional and morphological corneal changes before and after instillation were evaluated through ophthalmic examinations including breakup time of tear film (BUT) as measured by fluorescein staining and DR-1, Schirmer I test, Heidelberg Retina Tomograph II Rostock Cornea Module (HRTII-RCM), specular microscope, and Pentacum examination.

Results: Both the LVFX and MFLX groups had no significant change in each examination before and after instillation. There was also no statistically significant difference in measurements after the 7-day instillation between the groups.

Conclusion: Our study results suggest that as with LVFX, MFLX used in a normal clinical setting is unlikely to cause any obvious adverse effects on human normal cornea.

Keywords: cornea; fluoroquinolones; ocular surface; toxicity.

Figures

Figure 1
Figure 1
Corneal epithelial defects according to AD grading. After 7 days of instillation, corneal epithelial defects were observed in eight eyes of the subjects receiving MFLX and seven eyes of the subjects receiving LVFX. AD grading of the 15 eyes was A1D1 for 14 eyes and A2D1 for the remaining eye. No statistically significant difference between the groups was observed in the incidence of epithelial defects (P = 0.675, t-test).

References

    1. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986;29:1073–1078.
    1. Bezwada P, Clark LA, Schneider S. Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells. Curr Med Res Opin. 2008;24:419–424.
    1. O’Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33:1790–1800.
    1. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50 (Suppl 1):S32–S45.
    1. Miyata K, Amano S, Sawa M, Nishida T. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol. 2003;121:1537–1539.
    1. Yokoi N, Takehisa Y, Kinoshita S. Correlation of tear lipid layer interference patterns with the diagnosis and severity of dry eye. Am J Ophthalmol. 1996;122:818–824.
    1. Jalbert I, Stapleton F, Papas E, Sweeney DF, Coroneo M. In vivo confocal microscopy of the human cornea. Br J Ophthalmol. 2003;87:225–236.
    1. Ly LT, Cavanagh HD, Petroll WM. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Eye Contact Lens. 2006;32:161–165.
    1. Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology. 2007;114:1622–1629.
    1. Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007;33:63–68.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren